Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double‐blind, placebo‐controlled trial

Abstract

Efficacy and safety results from this clinical trial support a positive benefit-risk ratio for buprenorphine/naloxone sublingual tablet use in the treatment of an opioid-dependent Chinese population.